<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28344" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Clear Cell Renal Carcinoma (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padala</surname>
            <given-names>Sandeep A.</given-names>
          </name>
          <aff>Augusta UMC/ Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kallam</surname>
            <given-names>Avyakta</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Padala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Avyakta Kallam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28344.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Renal cell carcinoma (RCC) arises from the renal cortex or the renal tubular epithelial cells. It is classified into clear cell RCC (ccRCC), papillary RCC, and chromophobe RCC, accounting for about 85% of all the primary renal cancers. The other 15% constitutes of transitional cell carcinoma, Wilms tumor or nephroblastoma, tumors of the collecting ducts, and renal sarcomas.<xref ref-type="bibr" rid="article-28344.r1">[1]</xref>&#x000a0;They are heterogeneous diseases with different biology, genetics, and behavior. Overall, the incidence has been steadily increasing, and currently, it is the 7th most common cancer among men. Among the genitourinary cancers, RCC has the highest mortality rate. The increase in incidence could be attributed to incidental diagnosis. About 60% of the cases are detected incidentally.</p>
      </sec>
      <sec id="article-28344.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Renal cell carcinoma can develop due to genetic or acquired causes. The two most common genetic abnormalities are the Von Hippel&#x02013;Lindau (VHL) gene and the protein polybromo-1 (PBRM-1) gene. The common acquired causes include long-term dialysis dependence, history of smoking, long-term analgesic use, obesity, hypertension, and diabetes.<xref ref-type="bibr" rid="article-28344.r2">[2]</xref><xref ref-type="bibr" rid="article-28344.r3">[3]</xref> About 95% of the patients with ccRCC have a deletion in the short arm of chromosome 3 (loss of 3p). Screening for this is usually not recommended in healthy individuals.</p>
        <p>Screening should be considered in patients with high-risk characteristics such as VHL syndrome, tuberous sclerosis, long-term dialysis dependence (more than 3 years), especially in young patients, family history of RCC, and personal history of irradiation. Following renal transplantation, the risk of kidney cancer is 15 fold in the first three years and increases thereafter due to immunosuppressive therapy.<xref ref-type="bibr" rid="article-28344.r2">[2]</xref>&#x000a0;Patients&#x000a0;on long-term dialysis acquire cysts without any underlying history of the acquired cystic disease, called acquired cystic kidney disease (ACKD). When compared to the general population, patients with ACKD are at increased risk for papillary RCC.<xref ref-type="bibr" rid="article-28344.r3">[3]</xref>&#x000a0;Patients with polycystic kidney disease (PCKD) do not have any increased risk of RCC compared to the general population.</p>
      </sec>
      <sec id="article-28344.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Renal cell carcinoma is more prevalent in North America and the Czech Republic, with overall male predominance (male: females 2:1).<xref ref-type="bibr" rid="article-28344.r4">[4]</xref>&#x000a0;Every year, the number of reported cases in the United States is about 64,000, and the mortality is as high as 14,000. The incidence peaks from 60 to 80 years of age.<xref ref-type="bibr" rid="article-28344.r5">[5]</xref> Overall, the prognosis is worse in the&#x000a0;Black population.</p>
      </sec>
      <sec id="article-28344.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Mutations in the VHL gene can be transmitted in an autosomal dominant fashion or in a sporadic way. More than 50% of the patients with ccRCC sporadically have VHL gene abnormalities.<xref ref-type="bibr" rid="article-28344.r6">[6]</xref>ouble hit theory is that some patients are born with one copy of defective VHL gene, and the second hit is due to the somatic mutation.&#x000a0;Normally, VHL is a tumor suppressor gene that regulates the levels of intracellular proteins and hypoxia-inducible factor 1 alpha and 2 alpha (HIF1A and HIF2A).<xref ref-type="bibr" rid="article-28344.r7">[7]</xref><xref ref-type="bibr" rid="article-28344.r8">[8]</xref></p>
        <p>A defective VHL gene results in the interaction among intracellular proteins resulting in the upregulation of messenger RNA (mRNA) encoding for growth factors such as platelet-derived growth factor-beta (PDGFB), vascular endothelial cell growth factor (VEGF), and transforming growth factor-alpha (TGFA). All these growth factors promote the development of these vascular tumors.&#x000a0;Under normal oxygen conditions, HIF1A and HIF2A undergo hydroxylation and binds to a protein called pVHL and are degraded. In hypoxemic conditions or the absence of pVHL, HIFA accumulates, leading to the upregulation of mRNA and increased production of the growth factors.<xref ref-type="bibr" rid="article-28344.r8">[8]</xref><xref ref-type="bibr" rid="article-28344.r9">[9]</xref></p>
      </sec>
      <sec id="article-28344.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>ccRCC and papillary RCC arise from proximal tubule epithelial cells, whereas the chromophobe RCC and collecting duct tumors arise from the distal tubules.</p>
      </sec>
      <sec id="article-28344.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Usually, patients are asymptomatic until the malignancy has advanced. The classic symptoms include flank pain, hematuria, and palpable renal mass and are seen in only 9% of the cases. The classical triad is seen in advanced disease.<xref ref-type="bibr" rid="article-28344.r5">[5]</xref>&#x000a0;Flank pain is due to the mass effect or stretch of the renal capsule. The hematuria is due to tumor infiltration into the renal medulla and collecting ducts. It can be differentiated from the glomerular bleed by the absence of acanthocytes/ red cell casts on the microscopy. Depending on the extent of bleeding, the patients can complain of passing clots and colicky pain.</p>
        <p>On physical examination, an abdominal mass can be palpable, which moves with respiration. The examination of the testes is to evaluate for left-sided varicocele as the left-sided spermatic vein drains into the left renal vein. The five years of life span was better in individuals with an incidental diagnosis of RCC. The common metastatic sites are lungs, bones, and brain. Erythrocytosis can be due to increased erythropoietin and impaired breakdown of hypoxia-inducible factors (HIFs) under normal oxygen concentrations.&#x000a0;</p>
        <p>Patients with tuberous sclerosis present with benign tumors in various organs including, kidneys, liver, lung, brain, heart, eyes, and skin. It is characterized by ash-leaf spots, shagreen patches, hamartomas, and angiomyolipomas, whereas, VHL is characterized by hemangioblastomas and benign and malignant tumors. Bilateral RCCs are more common in patients with papillary RCC, underlying history of VHL disease, and tuberous sclerosis.</p>
      </sec>
      <sec id="article-28344.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Higher rates of diagnosis of renal cell carcinoma are due to an incidental diagnosis. A thorough history, physical examination, including a testicular exam, is needed. Imaging studies, including ultrasound (US) or computed tomography (CT), are indicated. The US is a good test for the evaluation of simple and complex cysts. Bosniak classification guides us in managing renal cysts. CT with intravenous contrast is a better study than the US. Magnetic resonance imaging (MRI) is better for evaluating the extent of the disease when there is a contraindication to use the contrast or the inconclusive US or CT scan. The choice of test for metastatic RCC is MRI or a positron emission tomography (PET-CT). CT urography is better in evaluating the collecting system.&#x000a0;</p>
        <p>Bosniak classification of renal cysts:</p>
        <list list-type="bullet">
          <list-item>
            <p>Category I- Non-enhancing cyst - A benign cyst is characterized by a smooth border without any calcification or echoes in the cyst (anechoic). It has a thin wall without any septations or calcification or solid component. No risk of malignancy and no follow-up is needed.</p>
          </list-item>
          <list-item>
            <p>Category II- Less than 3 cm benign cyst with few thin septations or fine calcification. No, follow up needed.</p>
          </list-item>
          <list-item>
            <p>Category IIF- Greater than 3 cm benign cyst with few thin septations or fine calcification. "F" refers to follow-up with imaging in 6 months.</p>
          </list-item>
          <list-item>
            <p>Category III- Cysts with irregular walls or thick septations with cystic masses. Enhancement is seen. About 60% of the cysts have the risk of malignant transformation.</p>
          </list-item>
          <list-item>
            <p>Category IV and category III and solid mass or nodules or necrotic contents. Malignancy risk is around 90%.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28344.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Stages 1 to 3 are characterized as localized, and stage 4 is advanced disease. The treatment for localized disease is surgery with curative intent. Radical nephrectomy or partial nephrectomy is preferred depending upon the extent of the disease, patient's comorbidities, and underlying renal function.&#x000a0;Cryotherapy and radiofrequency ablation are reserved for unresectable or nonsurgical candidates presenting with a small renal mass.&#x000a0;Tyrosine kinase inhibitors (sunitinib and pazopanib) are used in metastatic ccRCC as they act by inhibiting VEGFR.&#x000a0;The mammalian target of rapamycin (mTOR inhibitors) everolimus and temsirolimus have been approved for metastatic ccRCC.<xref ref-type="bibr" rid="article-28344.r6">[6]</xref>&#x000a0;mTOR inhibitor, along with lenvatinib (VEGFR inhibitor), is used as a second-line agent in metastatic ccRCC.&#x000a0;The use of selective HIF2 blockers is under investigation.</p>
      </sec>
      <sec id="article-28344.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Simple cyst</p>
          </list-item>
          <list-item>
            <p>Angiomyolipoma</p>
          </list-item>
          <list-item>
            <p>Metastatic lesion</p>
          </list-item>
          <list-item>
            <p>Renal infarction</p>
          </list-item>
          <list-item>
            <p>Acquired cystic kidney disease (ACKD)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28344.s10" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Following surgical resection, there is no clear role for chemotherapy or immunotherapy in renal cell carcinoma. Tyrosine kinase inhibitors (sunitinib and pazopanib), mTOR inhibitors (everolimus and temsirolimus) have been approved for metastatic ccRCC.&#x000a0;mTOR inhibitor, along with lenvatinib (VEGFR inhibitor), is used as a second-line agent in metastatic ccRCC.</p>
      </sec>
      <sec id="article-28344.s11" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>TNM Staging per American Joint Committee on Cancer</bold>
<xref ref-type="bibr" rid="article-28344.r7">[7]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>TX- Unable to assess the primary</p>
          </list-item>
          <list-item>
            <p>T0-&#x000a0;Without any&#x000a0;evidence of the primary</p>
          </list-item>
          <list-item>
            <p>T1- Localization to the kidney, less than 7 cm (T1a is less than 4 cm, and T1b is greater than 4 cm, but less than 7 cm)</p>
          </list-item>
          <list-item>
            <p>T2-&#x000a0;Localization to the kidney, greater than 7 cm (T2a is less than 10 cm, and T2b is greater than 10 cm)</p>
          </list-item>
          <list-item>
            <p>T3- Invasion of the tumor into the blood vessels and perinephric region, but not beyond Gerota's fascia (T3a- when there is no&#x000a0;spread beyond the Gerota's fascia: T3b- involves infra diaphragmatic vena cava; T3c- Invasion of the supradiaphragmatic vena cava or the vena cava wall)</p>
          </list-item>
          <list-item>
            <p>T4- Invasion of the tumor beyond Gerota's fascia into the ipsilateral adrenal gland</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>NX- Unable to assess the regional lymph nodes</p>
          </list-item>
          <list-item>
            <p>N0- No evidence of regional lymph node involvement</p>
          </list-item>
          <list-item>
            <p>N1- When there is evidence of regional lymph nodes&#x000a0;involvement&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>M0- No evidence of metastasis</p>
          </list-item>
          <list-item>
            <p>M1- Evidence of&#x000a0;widespread metastasis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28344.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of metastatic ccRCC is poor, with a median survival of about 13 months and 5-year survival under 10%.<xref ref-type="bibr" rid="article-28344.r8">[8]</xref>&#x000a0;With the newer therapies, the overall survival has improved. Post-surgical resection, active surveillance is done to monitor for the development of additional RCCs. Carbonic anhydrase IX (CA-IX) is used for prognosis in advanced RCC.</p>
      </sec>
      <sec id="article-28344.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Paraneoplastic symptoms including hypercalcemia, erythrocytosis, hepatic dysfunction, secondary AA amyloidosis, and symptoms suggestive of polymyalgia rheumatica (PMR) are common complications.</p>
      </sec>
      <sec id="article-28344.s14" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>Urology</p>
          </list-item>
          <list-item>
            <p>Nephrology</p>
          </list-item>
          <list-item>
            <p>Oncology</p>
          </list-item>
          <list-item>
            <p>Genetics</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28344.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The only evidence for prevention includes a diet rich in fruit and vegetables and high vitamin D levels.<xref ref-type="bibr" rid="article-28344.r9">[9]</xref>&#x000a0;Serial monitoring of renal cysts is highly recommended, as about 30% of these lesions do not change their characteristics. About 35% of the cysts can grow faster, and the other&#x000a0;35% of the cysts&#x000a0;grow at a slower rate of 4 to 5 mm over 1 year.<xref ref-type="bibr" rid="article-28344.r10">[10]</xref>&#x000a0;Lesions less than 3 cm need to be monitored, whereas lesions that grow at a faster rate need surgical intervention despite being less than 3 cm.<xref ref-type="bibr" rid="article-28344.r11">[11]</xref></p>
      </sec>
      <sec id="article-28344.s16" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>It has been shown that about 40% of patients with renal cell carcinoma die, signifying the importance of additional studies and treatment modalities.<xref ref-type="bibr" rid="article-28344.r11">[11]</xref></p>
      </sec>
      <sec id="article-28344.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Renal cell carcinoma (RCC) arises from the renal cortex or the renal tubular epithelial cells. Overall, the incidence has been steadily increasing, and currently, it is the seventh most common cancer among men. Among the genitourinary cancers, RCC has the highest mortality rate. The prognosis of metastatic ccRCC is poor, with a median survival of about 13 months and 5-year survival under 10%. However, with newer therapies, overall survival has improved.&#x000a0;Usually, the patients are asymptomatic until the malignancy has advanced, which is the biggest challenge for early diagnosis. The classic symptoms include flank pain, hematuria, and palpable renal mass is seen in only 9% of the cases. Higher rates of diagnosis of RCC are due to an incidental diagnosis. The treatment involves an interprofessional team consisting of&#x000a0;a urologist, medical oncologist, nephrologist, and a genetic counselor. Patients with a family history should be educated about the possibility of acquiring cancer.</p>
      </sec>
      <sec id="article-28344.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28344&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28344">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28344/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28344">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28344.s19">
        <title>References</title>
        <ref id="article-28344.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsieh</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Purdue</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Signoretti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Swanton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Albiges</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schmidinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heng</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ficarra</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Renal cell carcinoma.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Mar</month>
            <day>09</day>
            <volume>3</volume>
            <fpage>17009</fpage>
            <pub-id pub-id-type="pmid">28276433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scandling</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Acquired cystic kidney disease and renal cell cancer after transplantation: time to rethink screening?</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>621</fpage>
            <page-range>621-2</page-range>
            <pub-id pub-id-type="pmid">17699473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vatandaslar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Renal cell carcinoma in transplant recipients with acquired cystic kidney disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>750</fpage>
            <page-range>750-6</page-range>
            <pub-id pub-id-type="pmid">17699492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nabi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Flaig</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Renal cell carcinoma: a review of biology and pathophysiology.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <fpage>307</fpage>
            <pub-id pub-id-type="pmid">29568504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skinner</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Vermillion</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Pfister</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Leadbetter</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases.</article-title>
            <source>Cancer</source>
            <year>1971</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>1165</fpage>
            <page-range>1165-77</page-range>
            <pub-id pub-id-type="pmid">5125665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rini</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Niethammer</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hariharan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Escudier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Mar</month>
            <day>10</day>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>752</fpage>
            <page-range>752-9</page-range>
            <pub-id pub-id-type="pmid">24297945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swami</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Nussenzveig</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Haaland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement.</article-title>
            <source>Ann Transl Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>Suppl 1</issue>
            <fpage>S18</fpage>
            <pub-id pub-id-type="pmid">31032299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>McGovern</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Renal-cell carcinoma.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Dec</month>
            <day>08</day>
            <volume>353</volume>
            <issue>23</issue>
            <fpage>2477</fpage>
            <page-range>2477-90</page-range>
            <pub-id pub-id-type="pmid">16339096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Navratilova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mates</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zaridze</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Janout</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kollarova</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bencko</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Matveev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Szesznia-Dabrowska</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Holcatova</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yeager</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chanock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rothman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boffetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Vitamin d pathway genes, diet, and risk of renal cell carcinoma.</article-title>
            <source>Int J Endocrinol</source>
            <year>2010</year>
            <volume>2010</volume>
            <fpage>879362</fpage>
            <pub-id pub-id-type="pmid">20049159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duffey</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Choyke</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Glenn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Venzon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Linehan</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>172</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-5</page-range>
            <pub-id pub-id-type="pmid">15201738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28344.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cairns</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Renal cell carcinoma.</article-title>
            <source>Cancer Biomark</source>
            <year>2010</year>
            <volume>9</volume>
            <issue>1-6</issue>
            <fpage>461</fpage>
            <page-range>461-73</page-range>
            <pub-id pub-id-type="pmid">22112490</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
